Literature DB >> 9425641

Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils.

A R Leff1, A Herrnreiter, R M Naclerio, F M Baroody, D A Handley, N M Muñoz.   

Abstract

We studied the effect of R-, S- and R,S-albuterol in inhibiting the eosinophil peroxidase (EPO) secretion caused by 10(-10) to 10(-6) M formyl-met-leu-phe + 5 micrograms/ml cytochalasin B (FMLP/CB) in non-allergic and allergic subjects. Total RAST score obtained for allergic subjects was 4.12 +/- 0.21 vs 0.36 +/- 0.17 for non-allergic subjects (P < 0.0001). Stimulated EPO secretion was comparable in allergic [2,051 +/- 567 ng/10(6) eosinophils (eos)] and non-allergic subjects [2,337 +/- 488 ng/10(6) eos (P = NS)]. At all concentrations used, both R- and R,S-enantiomers caused comparable (27-32%) inhibition of FMLP/CB stimulated secretion of EPO in allergic and non-allergic subjects. Pretreatment with S-albuterol caused no augmentation of EPO secretion in either allergic (115 +/- 34.6%) or non-allergic subjects (114 +/- 23.7%) subjects, and there was no significant difference in secretion caused by FMLP/CB alone in either experimental group. Similar results were obtained for subjects stratified according to serum IgE concentration. Our data demonstrate that both R- and R,S-albuterol are equivalently effective in inhibiting stimulated secretion of EPO in both normal and allergic subjects and that there is no paradoxical augmenting effect of S-albuterol in stimulated eosinophil secretion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425641     DOI: 10.1006/pupt.1997.0082

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  8 in total

Review 1.  Beta2-agonists and bronchial hyperresponsiveness.

Authors:  Clive P Page; Domenico Spina
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

2.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

3.  Regulation of adhesion of AML14.3D10 cells by surface clustering of beta2-integrin caused by ERK-independent activation of cPLA2.

Authors:  Shigeharu Myou; Xiangdong Zhu; Evan Boetticher; Yimin Qin; Saori Myo; Angelo Meliton; Anissa Lambertino; Nilda M Munoz; Kimm J Hamann; Alan R Leff
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

4.  Levalbuterol versus albuterol.

Authors:  Bill T Ameredes; William J Calhoun
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

5.  Anti-inflammatory and antinociceptive effects of salbutamol on acute and chronic models of inflammation in rats: involvement of an antioxidant mechanism.

Authors:  Hulya Uzkeser; Elif Cadirci; Zekai Halici; Fehmi Odabasoglu; Beyzagul Polat; Tugba Nurcan Yuksel; Seda Ozaltin; Fadime Atalay
Journal:  Mediators Inflamm       Date:  2012-05-14       Impact factor: 4.711

6.  Racemic salbutamol and levosalbutamol in mild persistent asthma: A comparative study of efficacy and safety.

Authors:  Rituparna Maiti; Chenimilla Nagender Prasad; Jyothirmai Jaida; Sruthi Mukkisa; Narendar Koyagura; Anuradha Palani
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

Review 7.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

8.  (R)-albuterol decreases immune responses: role of activated T cells.

Authors:  Marcela A Ferrada; Erin L Gordon; Kai Yu Jen; Hong Zhen He; Xin Lu; Leesa M Barone; Sepideh Amirifeli; David L Perkins; Patricia W Finn
Journal:  Respir Res       Date:  2008-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.